Category Genetics

A positive APP, PSEN1, or PSEN2 result can unlock trial eligibility or drug coverage a second-opinion visit might otherwise miss.

A list of pointed questions to bring to a second-opinion visit on familial Alzheimer's genetic testing, from gene-specific risk to insurance gaps.

A second opinion often hinges on testing the right family member first, in the right order, before the patient themselves.

Who orders the test, how the gene found changes the outlook, and why insurance planning should happen before, not after, the results arrive.

What the panel tests, what it costs across labs, and why insurance and referral criteria miss many true mutation carriers.

Breaks down exactly which gene the panel finds, who actually qualifies for it, and what counseling comes before and after a result.

A three-gene panel can confirm or rule out familial Alzheimer's, but a result changes insurance eligibility as much as care planning.

A list of the specific accuracy, coverage, and counseling questions to raise before ordering a familial Alzheimer's gene panel.

A gene-by-gene breakdown of how doctors decide who gets tested, what a negative result actually means, and when counseling is required first.

A three-gene panel answers whether a younger person's memory loss traces to one inherited mutation — and where its blind spots still leave families without an answer.